# CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock

Study · id `cardio:ct-nct05267886` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05267886](<https://clinicaltrials.gov/study/NCT05267886>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05267886

Browse, organ or system: Heart  
Browse, condition area: Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 346 participants.

## Technical summary

Registry record NCT05267886. Randomized; triple masking; primary purpose treatment. Start 2022-03-05 (actual); primary completion 2026-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 346 participants (planned count; ClinicalTrials.gov record NCT05267886, source copy `cardio:ctgov-nct05267886-2026-05-01`, retrieved 2026-10-31)
- Started: 2022-03-05 (actual) (ClinicalTrials.gov record NCT05267886, source copy `cardio:ctgov-nct05267886-2026-05-01`, retrieved 2026-10-31)
- Primary completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT05267886, source copy `cardio:ctgov-nct05267886-2026-05-01`, retrieved 2026-10-31)
- Completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT05267886, source copy `cardio:ctgov-nct05267886-2026-05-01`, retrieved 2026-10-31)
- Countries: United States; Canada (ClinicalTrials.gov record NCT05267886, source copy `cardio:ctgov-nct05267886-2026-05-01`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05267886-2026-05-01`, retrieved 2026-10-31)

## The registry's words

- Brief title: CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock
- Acronym: DOREMI-2
- Condition: Shock, Cardiogenic
- Intervention (Drug): Dobutamine
- Intervention (Drug): Milrinone
- Intervention (Drug): Normal Saline
- Lead sponsor: Ottawa Heart Institute Research Corporation
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Cardiogenic shock (`cardio:cardiogenic-shock`)
- Registry intervention name matches this record: Dobutamine (`cardio:dobutamine`)
- Registry intervention name matches this record: Milrinone (`cardio:milrinone`)
- Registry lists this organization as the lead sponsor: Ottawa Heart Institute Research Corporation (`cardio:org-ottawa-heart-institute-research-corporation`)

## Provenance

Content hash: 545022289f229bda15d38e89240975f6010e160d46d4d121e1466f766cbc6d21
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
